L-Cycloserine
- Generic Name
- L-Cycloserine
- Brand Names
- Seromycin
- Drug Type
- Small Molecule
- Chemical Formula
- C3H6N2O2
- CAS Number
- 339-72-0
- Unique Ingredient Identifier
- AK7DRB7FMO
- Background
Antibiotic substance produced by Streptomyces garyphalus.
- Indication
本品与其他抗结核药联合，用于经一线药物（如吡嗪酰胺、链霉素、异烟肼、利福平和乙胺丁醇）治疗失败的患者。本品还可用于治疗非结核分枝杆菌感染如鸟复合分枝杆菌病的治疗。
- Associated Conditions
- Pulmonary Tuberculosis (TB), Tuberculosis, Extrapulmonary, Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection
- Associated Therapies
- -
D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 27
- Registration Number
- NCT00780442
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT00742079
- Locations
- 🇺🇸
MGH Schizophrenia Program - Freedom Trail Clinic, Boston, Massachusetts, United States
Veteran Stress and Learning Study
- Conditions
- Interventions
- First Posted Date
- 2008-05-08
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 111
- Registration Number
- NCT00674570
- Locations
- 🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
D-Cycloserine Enhancement of Exposure in Social Phobia
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 169
- Registration Number
- NCT00633984
- Locations
- 🇺🇸
Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Boston, Massachusetts, United States
The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Yale University
- Target Recruit Count
- 20
- Registration Number
- NCT00633256
- Locations
- 🇺🇸
West Haven VA, West Haven, Connecticut, United States
Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 25
- Registration Number
- NCT00632632
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Drug Discrimination in Methadone-Maintained Humans Study 1
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2011-03-11
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00593463
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
fMRI Study Examining Effects of D-cycloserine in Specific Phobia
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT00591825
- Locations
- 🇺🇸
University of Kansas Medical Center, Hoglund Brain Imaging Center, Kansas City, Kansas, United States
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
- Conditions
- Interventions
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Boston University Charles River Campus
- Target Recruit Count
- 169
- Registration Number
- NCT00515879
- Locations
- 🇺🇸
Boston University, Boston, Massachusetts, United States
Effects of Weekly Dosing of D-cycloserine on Cognitive Function in Individuals With Schizophrenia
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2014-08-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT00455702
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.